Will GSK stock test GBX1,765 resistance as Chai Discovery research deal makes headlines?

Traders Union
All News
Stocks
GSK gains 0.26% today to GBX1,759

Highlights

GSK formed a partnership with Chai Discovery to use AI-based protein design technology for early-stage drug research.
Internal results show Chai Discovery's models produced effective hits against every drug discovery target tested by GSK.
Shares of GSK trade below key moving averages with bearish momentum signals, indicating a projected range of GBX1,736 to GBX1,781 and a 67% probability of further downside.

AI partnership with Chai Discovery drives innovation narrative shift

GSK has entered into a collaboration with Chai Discovery to leverage AI-driven protein design in its drug research efforts, according to Finance Yahoo. Access to Chai Discovery's advanced protein folding and design models allows GSK to enhance its early-stage drug discovery, demonstrated by internal evaluations showing effective hits against all tested targets. This strategic move is likely to be seen as a step toward strengthening GSK's innovation pipeline, with potential to influence longer-term sentiment around its research initiatives.

Downside signals as GSK tests technical resistance, mixed momentum

On the technical side, GSK is trading below its MA-20 at GBX1,760 and MA-50 at GBX1,767 on the H1 chart, as well as under the long-term MA-200 at GBX1,951 on the daily timeframe. The Ichimoku Kijun sits at GBX1,765, acting as immediate resistance. Among momentum signals, MACD shows a strong sell, ADX remains neutral, while RSI at 46.56 and CCI both signal sell conditions. Stochastic RSI indicates potential for a short-term buy, Bull/Bear Power is oversold, and the Awesome Oscillator (AO) supports the prevailing seller bias. The current price is positioned close to mid-range, pointing to moderate volatility within an established corridor.

Rangebound outlook as volatility bands cap breakout risk

In the short term, GSK is likely to remain rangebound, fluctuating between GBX1,736 and GBX1,781 in line with typical volatility bands for this period. The probability of a move lower is estimated at 67%, with a 33% chance of an upward breakout. The base case anticipates continued sideways price action within this corridor. A decisive break above GBX1,765 would open up a bullish scenario, while a sustained drop below GBX1,736 would tilt outlook more negative.

Anton Kharitonov, expert at Traders Union, believes GSK's technical setup remains defensive despite news of the Chai Discovery partnership. He notes the stock trades below key moving averages, with momentum signals still suggesting downside risk. The collaboration may aid long-term innovation, but near-term sentiment is constrained by technical resistance and persistent seller bias. "Until GSK reclaims GBX1,765, the case for upside is unconvincing."

Previously it was reported that GSK planned a significant investment to expand its biopharmaceutical manufacturing and research operations in Pennsylvania. The current technical setup suggests that traders should closely monitor GBX1,736 as a potential downside risk, given the elevated probability of a further move lower in the near term.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.